Δ9-tetrahydrocannabinol

Phase 1Small molecule

UUniversity of California, San Diego

Δ9-tetrahydrocannabinol is one of 54 small molecule programs targeting Cognition. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

CognitionRecruiting

CognitionPhase 1

Recruiting

Competition

Competitive Landscape

88 competitors in Cognition

#DrugCompanyPhaseTrials

Neurontin

VViatris Specialty LLC

Approved

1 2

Accutane

CConrado Roberto Hoffmann Filho

Approved

1 3

Ambien

PPurdue Pharma LP

Approved

1 4

Osmitrol

BB. Braun Medical Inc.

Namenda

3 6

Epidiolex

Jazz Pharmaceuticals

Phase 2

2 7

Nuplazid

AACADIA Pharmaceuticals Inc.

Phase 2

1 8

Remimazolam Tosilate

FFujian Shengdi Pharmaceutical Co., Ltd.

Phase 3

1 9

Psilocybin

COMPASS Pathways

Phase 2

1 10

Ketalar

Boehringer Ingelheim

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Cognition1 trial

Cannabis Use, Cognition, and the Endocannabinoid System in HIV

Recruiting·UUniversity of California, San Diego·Phase 1·NCT04883255·138 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Δ9-tetrahydrocannabinol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Δ9-tetrahydrocannabinol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Δ9-tetrahydrocannabinol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of California, San Diego company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: UUniversity of California, San Diego

Δ9-tetrahydrocannabinol

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Cognition1 trial

References

Drug Info

Quick Facts

Related News